View Post

Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™

In Clinical Studies News by Barbara Jacoby

From: Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed Trodelvy is the first antibody-drug conjugate (ADC) shown to improve clinical outcomes in people with relapsed or refractory mTNBC who have …